2003Zhongguo tangniaobing zazhiRequires access

The kidney-protective effect of valsartan in type 2 diabetic rats

Jiao Xiu

Open publisher page 0 citations

Abstract

Objective To investigate the mechanism of valsartan in protecting the kidney in type 2 diabetic rats. Methods The fat fed ,strepozotocin treated rats were served as experimental animal model. Adult female Sprague Dawley rats ( n =10 in each group) were studied:normal control rats,diabetic rats and diabetic rats treated with valsartan (10 mg· -1 ·d -1 , Plasma glucose,serum insulin,serum creatinine,urinary albumin,BUN and profile of kidney hypertrophy were observed after 10 weeks of treatment. PAI 1 protein expression was measured by immunohistochemistry. Results Urinary albumin excretin( P 0.01)、BUN( P 0.05)and kidney hypertrophy index( P 0.05)of valsartan treated group were significantly lower than those of diabetic group. The protein expression of PAI 1 in the valsartan group was lower than that in the diabetic group. Conclusion Valsartan may has kidney protective effect on diabetic rats,partly through down regulated PAI 1expression

About this research paper

What this paper is about

Objective To investigate the mechanism of valsartan in protecting the kidney in type 2 diabetic rats. Methods The fat fed ,strepozotocin treated rats were served as experimental animal model. Adult female Sprague Dawley rats ( n =10 in each group) were studied:normal control rats,diabetic rats and diabetic rats treated with valsartan (10 mg· -1 ·d -1 , Plasma glucose,serum insulin,serum creatinine,urinary albumin,BUN and profile of kidney hypertrophy were observed after 10 weeks of treatment. PAI 1 protein expression was measured by immunohistochemistry. Results Urinary albumin excretin( P 0.01)、BUN( P 0.05)and kidney hypertrophy index( P 0.05)of valsartan treated group were significantly lower than those of diabetic group. The protein expression of PAI 1 in the valsartan group was lower than that in the diabetic group. Conclusion Valsartan may has kidney protective effect on diabetic rats,partly through down regulated PAI 1expression

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective To investigate the mechanism of valsartan in protecting the kidney in type 2 diabetic rats. Methods The fat fed ,strepozotocin treated rats were served as experimental animal model. Adult female Sprague Dawley rats ( n =10 in each group) were studied:normal control rats,diabetic rats and diabetic rats treated with valsartan (10 mg· -1 ·d -1 , Plasma glucose,serum insulin,serum creatinine,urinary albumin,BUN and profile of kidney hypertrophy were observed after 10 weeks of treatment. PAI 1 protein expression was measured by immunohistochemistry. Results Urinary albumin excretin( P 0.01)、BUN( P 0.05)and kidney hypertrophy index( P 0.05)of valsartan treated group were significantly lower than those of diabetic group. The protein expression of PAI 1 in the valsartan group was lower than that in the diabetic group. Conclusion Valsartan may has kidney protective effect on diabetic rats,partly through down regulated PAI 1expression

Key concepts: Valsartan, Internal medicine, Endocrinology, Medicine, Creatinine, Kidney, Renal Hypertrophy, Diabetes mellitus

Related papers

Back to paper searchBrowse research topicsOriginal source
The kidney-protective effect of valsartan in type 2 diabetic rats — Research Paper | ScholarLens